



WEEKLY WRAP-UP

12TH JANUARY - 16TH JANUARY 2026

PROGRESSIVE®
Your Progress Our Priority...

HIGHLIGHTS OF THE WEEK

12 Jan 2026-16 Jan 2026

DOMESTIC:

- Dr. Reddy's launches first-to-market generic Olopatadine eye drops in US market
- Zydus Lifesciences gets USFDA nod for generic blood disorder drug
- Cochin Shipyard delivers first multi-purpose vessel to Germany's HS Schiffahrts
- Biocon raises Rs4,150cr via QIP issue on strong investor demand
- Transrail Lighting secures orders worth Rs5.27bn
- BHEL commences supply of semi-high-speed underslung traction transformers for Vande Bharat sleeper train project
- Andhra Cements promoter reduces stake by 7.76% to meet minimum public shareholding requirements
- Endurance Technologies gets enhanced incentive eligibility
- NLC India signs Rs25,000cr renewable energy MoU with Gujarat Government
- IHCL announces its 28th hotel in Tamil Nadu
- VA Tech Wabag wins order worth upto Rs600cr from BPCL for Madhya Pradesh project
- Larsen and Toubro clarifies Kuwait oil project tenders not in order book
- Firstsource Solutions acquires TeleMedik for USD3mn to expand US healthcare presence
- Maruti Suzuki Board approves land acquisition for second plant in Gujarat
- Sical Logistics secures Rs40.38bn contract from South Eastern Coalfields
- HCL Technologies partners with Magnum Ice Cream for digital infrastructure modernization
- NBCC arm HSCC signs MoU with Bharat Electronics for healthcare manufacturing, services
- Shakti Pumps wins first solar pump order from KREDL worth Rs654cr
- KP Energy signs Rs4,000cr MoU with Gujarat government for 855MW renewable energy projects
- Reliance says battery manufacturing plans on track, 2026 target unchanged
- PFC plans to raise up to Rs5,000cr through public issue of NCDs
- Bajaj Auto plans to take Chetak EV scooters to over 100 countries
- Tata Motors ramps up capacity amid strong demand for Sierra, Punch
- RedTape founders look to sell majority stake, approach Blackstone, KKR
- Taj Hotels parent IHCL buys majority stake in Brij Hotels for Rs193cr
- Godrej Properties reports bookings worth Rs8,421cr in October-December
- NTPC Green Energy to form 50:50 JV with GAIL for setting up RE projects
- Maruti signs MoU with IOCL to set up service stations at fuel outlets

ECONOMY:

- India likely to sign trade deal with EU by January end, negotiations to conclude by 26th Jan
- India Inc flags Budget levers to unlock private capex
- India sees strong 3rd quarter growth, IMF likely to hike GDP forecast

INDUSTRY:

- Budget may fund new drug testing labs, regulatory manpower
- India's exports to China surges 67.35% in December: Commerce Ministry data
- India overhauls customs duty rules to help exporters and smaller businesses

HIGHLIGHTS OF THE WEEK

12 Jan 2026-16 Jan 2026

COVERAGE NEWS:

Lloyds Engineering Works Ltd: The company has entered into a licensing and purchase agreement with The Materials Works Ltd (TMW), USA to enable LEWL to design, manufacture and sell EPS Gen 4 cells across the globe excluding China, Macao, Hong Kong and Taiwan.

Royal Orchid Hotels Ltd: (i) The company has signed a new property Regenta Place Udaipur (43 keys) to be operated under a management agreement, (ii) The company has signed a new resort under its brand Regenta Place at Jim Corbett (50 keys).

Alembic Pharmaceuticals Ltd: The company has received USFDA tentative approval for Bosutinib Tablets, 400mg. According to IQVIA, the tablets had an estimated market size of USD251mn for twelve months ending Sept'25.

Metropolis Healthcare Ltd: The company has launched centre of genomics where MHL will deploy Illumina's NovaSeq X Series to strengthen genomic research and broaden access to advanced insights.

Shilpa Medicare Ltd: Koanna Healthcare Canada Inc., (WoS of Shilpa Medicare) has allotted 28,421,020 equity shares for a total consideration of CAD2000 pursuant to share sale-purchase agreement. Consequent to the investment already done, Koanna Healthcare Canada Inc. ceases to be a WoS of Shilpa Medicare.

Cipla Ltd: With regard to the USFDA inspection conducted at Pharmathen (manufacturer and exclusive supplier of Lanreotide injection to Cipla USA Inc.), the production has been temporarily paused to support ongoing remediation efforts and the re-supply of Lanreotide is expected to resume in H1FY27.

Sun Pharmaceutical Industries Ltd: The company has announced the availability of Unloxcyt for the treatment of adults in the US with metastatic cutaneous squamous cell carcinoma.

Ajanta Pharma Ltd: The company has incorporated its WoS named as Ajanta Pharma Ireland Ltd.

Zen Technologies Ltd: The company has received orders (from the MoD) worth Rs3320mn for the supply of anti-drone systems/ counter unmanned aerial systems and Rs720mn for training simulators and equipment.

The Week That Went By:

Extending its pessimistic trend, Nifty50 began the truncated week on a weak note and extended its losses to test the strong support level of 25,450. As oversold conditions emerged, the Index witnessed a sharp rebound from lower levels and managed to recoup all its losses. On the 2nd trading day, the market opened steadily but failed to sustain higher levels, eventually giving up all its gains. The 3rd trading day remained highly volatile, with sharp swings on both sides. Supported by strength in the IT counters and select heavyweight stocks, the Index started the final trading day on a firm note and added to its gains; however, it once again pared most of the gains and finally settled the week at 25,694.35, up marginally by 11.05 points. On the sectoral front, the Capital Market Index emerged as the top performer, advancing over 5%, followed by PSU Banks and Metals. Realty and Pharma were the major laggards. Mid & Smallcaps rose by 0.20% and 0.46%, respectively, outperforming Nifty50.

Nifty50=25,694.35

Sensex30=83,570.35

Nifty Midcap 100=59,867.80

Nifty Smallcap100=17,362.30

HIGHLIGHTS OF THE WEEK

12 Jan 2026-16 Jan 2026

NIFTY (WEEKLY)



BANK NIFTY (WEEKLY)



MARKET OUTLOOK

A classic DOJI candlestick pattern on **Nifty50's** weekly chart reflects clear indecisiveness between bulls and bears. During the week, the Index reversed twice from 25,870 level, showing it as a strong resistance. On the downside, 25,600 is expected to act as an immediate support. A decisive breakout on either sides of this range will offer clearer direction. **Bank Nifty** is much stronger compared to Nifty50 and contains sufficient momentum to surpass its recent highs. The level of 60,400 stands as immediate resistance, while 59,730 is expected to provide nearby support. The **Capital Market Index** has witnessed a breakout from a Symmetrical Triangle pattern, indicating trend continuation. However, formation of a Shooting Star candlestick on the daily chart raises short-term caution. Hence, confirmation from next week's price action will be crucial. Several stocks within the sector are on the verge of key breakouts (**Angel One and 360ONE- Near Symmetrical Triangle breakouts; BSE- On the verge of a Cup-and-Handle breakout**). The **IT sector** also warrants close attention, as it appears to be nearing the end of its consolidation phase through a Cup & Handle formation. A strong rally can be anticipated post a confirmed breakout (**Infosys-Ascending Triangle breakout; Tech Mahindra-Symmetrical Triangle breakout**). Meanwhile, the **Metal and PSU Banking sectors** remain in strong uptrends with a series of higher-top, higher-bottom structures. Select stocks from both segments have already confirmed breakouts from their respective patterns (**SAIL- Cup-and-Handle breakout; Tata Steel- Rounding Bottom breakout; Bank of India-Rounding Bottom breakout; Bank of Maharashtra- Ascending Triangle breakout**).


HIGHLIGHTS OF THE WEEK

12 Jan 2026-16 Jan 2026

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	0.11%	HDFC Life	(2.20%)	Reliance	(1.02%)
Adani Ports	(0.70%)	Hindalco	3.10%	SBI Life	0.27%
Apollo Hospital	(0.34%)	HUL	(0.31%)	SBIN	4.05%
Asian Paints	(2.90%)	ICICI Bank	0.57%	ShriRam Finance	2.01%
Axis Bank	1.69%	Indigo	(2.22%)	Sun Pharma	(3.79%)
Bajaj Auto	(0.96%)	INFY	4.47%	Tata Consumer	0.77%
Bajaj Finserv	0.65%	ITC	(2.73%)	Tata Steel	5.32%
Bajaj Finance	(1.09%)	JioFin	(3.34%)	TCS	(0.11%)
BEL	(1.76%)	JSW Steel	2.40%	Tech Mahindra	5.61%
Bharti Airtel	(0.64%)	Kotak Bank	(1.56%)	TITAN	(0.25%)
Cipla	(4.64%)	LT	(4.05%)	TMPV	(0.32%)
Coal India	2.76%	M&M	(0.52%)	Trent	(2.08%)
Dr. Reddy's Labs	(2.90%)	Maruti	(3.78%)	UltraTech	3.89%
Eicher Motors	(2.80%)	Max Healthcare	1.61%	Wipro	1.64%
Eternal	1.16%	Nestle India	1.24%		
Grasim	1.37%	NTPC	2.88%		
HCL Tech	2.07%	ONGC	5.61%		
HDFC Bank	(0.90%)	PowerGrid	(0.75%)		

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK

12 Jan 2026-16 Jan 2026

SECTORAL GAINER



The **Capital Market Index** surged by 5.01% and outperformed Nifty50. **Angelone (+17.06%)** and **MCX (+11.95%)** emerged as the top performers among the components, followed by **Motilal Oswal (+5.21%)** and **BSE (+4.66%)**, while **Anand Rathi (1.75%)** and **NAM-India (1.34%)** were the laggards. The sector has given a breakout from a **Symmetrical Triangle pattern**, which indicates a trend continuation, but on the daily chart, it has formed a **shooting star candlestick pattern**, which is not so encouraging; thus, we will wait for next week's activity for confirmation.

SECTORAL LOSER



With a loss of 2.40%, the **Realty sector** underperformed the Benchmark Index. Barring **Lodha (+0.57%)**, all the components ended the week in red with **Signature (8.59%)** and **Godrej Properties (5.37%)** being the major laggards. As shown in the chart, the sector has given a breakdown from a **Descending Triangle Formation**, pointing towards a bearish trend continuation, and the activity of the upcoming week will provide confirmation.

HIGHLIGHTS OF THE WEEK

12 Jan 2026-16 Jan 2026

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai-400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500

Grievance Officer:
Email: grievancecell@progressiveshares.com